|Hepatocellular Carcinoma||Phase 3|
|Metastatic Colorectal Cancer||Phase 3|
|Benign Prostatic Hyperplasia||Phase 2|
Current Clinical Trials
LSO has completed Aptocine treatment in a Phase 3 trial in hepatocellular carcinoma and in a Phase 3 trial in colorectal cancer metastatic to the liver. LSO has also completed treatment in Phase 1 and Phase 2 clinical trials in benign prostatic hyperplasia (BPH).
About Light Sciences Oncology
Light Sciences Oncology (LSO) is developing Aptocine™ (talaporfin sodium) for solid tumors as well as other indications such as BPH. Aptocine is a water-soluble drug targeted by a small, single-use, disposable drug activator included with the drug. Aptocine is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment of patients in a Phase 3 trial of Aptocine in hepatocellular carcinoma (HCC), a Phase 3 trial for metastatic colorectal cancer (MCRC) and in Phase 1 and Phase 2 clinical trials in benign prostatic hyperplasia (BPH), or enlargement of the prostate. The company has positioned Aptocine to benefit an increasing number of patients with a strong portfolio of intellectual property, innovative applications in development, and an exceptionally capable and efficient team.
Aptocine has three potential primary mechanisms of action: direct tumor cytotoxicity, apoptosis due to vascular shutdown, and anti-tumor immune stimulation. In clinical studies to date, Aptocine has been well-tolerated with no evidence that Aptocine causes the serious toxicities associated with traditional cancer treatments.
Aptocine has been identified during development as Litx™.